Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: squetch who wrote (20650)	5/13/1998 8:19:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Stan, Thanks for the update. I was using Lehman Brothers summary. They missed the presentation of Targretin data on Head & Neck as well as the Panretin combo data (with Tamoxifen) for breast cancer. Have you seen the breast cancer abstract? The ASCO presentation is on one of two combo trials of Panretin with Tamoxifen for the treatment of breast cancer, and positive data could capture quite a bit of media attention.